

Docket No.: DECLE55.1CP2DV

1644 Sequence listing  
Customer No.: 20,995

**AMENDMENT / RESPONSE TRANSMITTAL**

Applicant : Moser, et al.  
App. No. : 09/802,397  
Filed : March 9, 2001  
For : DENDRITIC-LIKE  
CELL/TUMOR CELL  
HYBRIDS AND  
HYBRIDOMAS FOR  
INDUCING AN ANTI-  
TUMOR RESPONSE  
  
Examiner : Ewoldt, Gerald R.  
Art Unit : 1644

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 9, 2004  
(Date)

*Che S. Chereskin*  
Che Swyden Chereskin, Ph.D., Reg. No. 41,466

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

- (X) Supplemental Amendment and Paper to Comply with the Sequence Rules in 4 pages.
- (X) Sequence Listing in 3 pages.
- (X) Return prepaid postcard.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

*Che S. Chereskin*  
Che Swyden Chereskin, Ph.D.  
Registration No. 41,466  
Agent of Record  
Customer No. 20,995  
(949) 760-0404

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant	:	Moser, et al.	)	Group Art Unit : 1644
			)	
Appl. No.	:	09/802,397	)	
			)	
Filed	:	March 9, 2001	)	
			)	
For	:	<b>DENDRITIC-LIKE CELL/TUMOR</b>	)	
		<b>CELL HYBRIDS AND</b>	)	
		<b>HYBRIDOMAS FOR INDUCING</b>	)	
		<b>AN ANTI-TUMOR RESPONSE</b>	)	
			)	
Examiner	:	Ewoldt, Gerald R.	)	

SUPPLEMENTAL AMENDMENT AND PAPER TO  
COMPLY WITH THE SEQUENCE RULES

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This paper is in anticipation of a Notice to Comply with the Sequence Rules and Supplemental to the Amendment filed November 10, 2003. Applicants respectfully request the Examiner to enter the following amendments and submit the following statement to invoke the procedures of 37 C.F.R. § 1.821(e).

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks** begin on page 4 of this paper.